Literature DB >> 1622169

Assay of fluconazole by high-performance liquid chromatography with a mixed-phase column.

J E Wallace1, S C Harris, J Gallegos, G Foulds, T J Chen, M G Rinaldi.   

Abstract

A mixed-phase liquid chromatographic column was used to assay fluconazole in plasma, serum, and cerebrospinal fluid. The assay was linear from 0.2 to 20 micrograms/ml, with an average coefficient of variation of less than 5%. The partitioning of the drug between serum and cerebrospinal fluid was determined for 34 patients. The method was demonstrated to be suitable for both pharmacokinetic studies and monitoring of patients receiving treatment with this antifungal agent.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1622169      PMCID： PMC190563          DOI： 10.1128/AAC.36.3.603

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Rapid determination of serum levels of a new antifungal agent, fluconazole, by high-performance liquid chromatography.

Authors:  K K Hosotsubo; H Hosotsubo; M K Nishijima; T Okada; N Taenaka; I Yoshiya
Journal:  J Chromatogr       Date:  1990-07-13

2.  Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection.

Authors:  S C Harris; J E Wallace; G Foulds; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

3.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

Authors:  C A Arndt; T J Walsh; C L McCully; F M Balis; P A Pizzo; D G Poplack
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

4.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

5.  Determination of fluconazole in biological fluids by capillary column gas chromatography with a nitrogen detector.

Authors:  D Debruyne; J P Ryckelynck; M C Bigot; M Moulin
Journal:  J Pharm Sci       Date:  1988-06       Impact factor: 3.534

6.  Fluconazole penetration into cerebrospinal fluid in humans.

Authors:  G Foulds; D R Brennan; C Wajszczuk; A Catanzaro; D C Garg; W Knopf; M Rinaldi; D J Weidler
Journal:  J Clin Pharmacol       Date:  1988-04       Impact factor: 3.126
  6 in total
  6 in total

Review 1.  Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature.

Authors:  G Weers-Pothoff; J F Havermans; J Kamphuis; H A Sinnige; J F Meis
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

2.  Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits.

Authors:  K Chemlal; L Saint-Julien; V Joly; R Farinotti; N Seta; P Yeni; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; F Caselli; A Novelli; S Fallani; D Giannini; D Arzeni; S Di Cesare; L F Di Francesco; M Fortuna; A Giacometti; F Carle; T Mazzei; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.

Authors:  Silvia Regina Cavani Jorge Santos; Edvaldo Vieira Campos; Cristina Sanches; David Souza Gomez; Marcus Castro Ferreira
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

Review 5.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

6.  Pharmacokinetics of fluconazole in pediatric patients.

Authors:  K W Brammer; P E Coates
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.